

GAU 1646
#6
1.7.7.P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Serial No. 09/163,713

Filed: September 30, 1998

For: *Nuclear Hormone Receptor Drug Screens*



Group Art Unit: 1646

Examiner: Pak, M.

Attorney Docket No. T97-012-1

FEB 10 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner of Patents Washington, DC 20231, on January 28 2000. R. A.

Signature 

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 (b)

The Assistant Commissioner for Patents
Washington D.C. 20231

Dear Commissioner,

In accordance with 37 C.F.R. §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant requests the Office to consider this Information Disclosure Statement under 37 C.F.R. §1.97 (b), accordingly no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R. §1.97 (h) the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any fees, if necessary, to Deposit Account No. 19-0750. (Order No. T97-012)

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP



Richard Aron Osman, Ph.D., #36,627
Telephone: (650)343-4341
Facsimile: (650) 343-4342